Stopping immunomodulatory medications in MS: Frequency, reasons and consequences.
Prolonged periods of disease quiescence during long term treatment of patients with clinically isolated syndrome and MS may prompt consideration of discontinuing disease-modifying therapy (DMT). We reviewed pertinent studies to identify the frequency and reasons for discontinuation of DMT.
Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
W O
WO
Tobin
Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: weinb@mayo.edu.
B G
BG
Weinshenker
D003657:Decision Making; D006801:Humans; D007155:Immunologic Factors / Q000191:economics / Q000627:therapeutic use*; D056747:Immunomodulation; D055118:Medication Adherence / Q000523:psychology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology; D028761:Withholding Treatment / Q000706:statistics & numerical data; D016903:Drug Monitoring
D007155:Immunologic Factors
Disease activity; Multiple sclerosis; Treatment discontinuation